When innovation meets immune activation, new possibilities emerge for melanoma care.
Research Advances
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
The CHALLENGE trial proves what we’ve long suspected: structured exercise isn’t just good for you—it can save your life.
When immune therapy clears cancer, the real question for resectable tumors becomes: Do we still need to resect?
From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.
ctDNA is helping us track what truly matters—real-time, personalized signals that guide smarter decisions in cancer care.
Immunotherapy’s success may hinge on what we preserve, not just what we prescribe.
Five groundbreaking trials from the ASCO Plenary are transforming cancer care—ushering in biomarker-led immunotherapy across multiple disease types.
For years, the treatment of esophageal carcinoma has been a subject of debate, with varying multimodal approaches tailored based on tumor location and staging. Traditionally, gastric cancer patients often underwent perioperative FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection. Meanwhile, esophageal carcinoma patients were typically treated with neoadjuvant chemoradiotherapy (CROSS regimen: carboplatin/paclitaxel with radiation) followed by surgery or upfront chemotherapy …
On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …